PET study using [ 11C]FTIMD with ultra-high specific activity to evaluate I 2-imidazoline receptors binding in rat brains

Nuclear Medicine and Biology

Volumn 39, Issue 2, 2012, Pages 199-206

  Kawamura, Kazunori ^a   Kimura, Yuichi ^a   Yui, Joji ^a   Wakizaka, Hidekatsu ^a   Yamasaki, Tomoteru ^a   Hatori, Akiko ^a   Kumata, Katsushi ^a   Fujinaga, Masayuki ^a   Yoshida, Yuichiro ^a,b   Ogawa, Masanao ^a,b   Nengaki, Nobuki ^a,b   Fukumura, Toshimitsu ^a   Zhang, Ming Rong ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b 141 0032   (Japan)

Author keywords

11C; FTIMD; I 2; Imidazoline receptors; PET; Ultra high specific activity

Indexed keywords

2 (2 IMIDAZOLIN 2 YL)QUINOLINE; 2 (3 FLUORO 4 TOLYL) 4,5 DIHYDRO 1H IMIDAZOLE C 11; CARBON 11; CHEMICAL COMPOUND; IMIDAZOLINE I2 RECEPTOR; LIGAND; METHANE; METHYL IODIDE; PALLADIUM; RADIOPHARMACEUTICAL AGENT; TRIBUTYLSTANNYL PRECURSOR; UNCLASSIFIED DRUG; 2 (3 FLUOROTOLYL) 4,5 DIHYDRO 1H IMIDAZOLE; 2-(3-FLUOROTOLYL)-4,5-DIHYDRO-1H-IMIDAZOLE; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTOR; IMIDAZOLINE RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; CROSS COUPLING REACTION; DISTRIBUTION VOLUME; DRUG ACTIVITY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; IODINATION; ISOTOPE LABELING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; ANIMAL; BRAIN; METABOLISM; METHODOLOGY; PROTEIN BINDING; SCINTISCANNING; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; BRAIN; IMIDAZOLES; IMIDAZOLINE RECEPTORS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84856348553     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.07.008     Document Type: Article

References (26)

1. Hume S.P., Gunn R.N., Jones T. Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals. Eur J Nucl Med 1998, 25:173-176.
2. 11C]Ro15-4513 and its application in an extremely low concentration region to an ARG study. Nucl Med Biol 2003, 30:335-343.
3. Kung M.P., Kung H.F. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 2005, 32:673-678.
4. 11C]raclopride with ultrahigh specific activity in rat brain determined by homogenate assay and autoradiography. Nucl Med Biol 2008, 35:19-27.
5. 11C]DAC with ultra-high specific activity. Synapse 2010, 64:488-493.
6. 11C]DAC with ultra-high specific activity. Neuroimage 2011, 54:123-130.
7. Molderings G.J. Imidazoline receptors: basic knowledge, recent advances, and future prospects for therapy and diagnosis. Drug Future 1997, 22:757-772.
8. Tesson F., Prip-Buus C., Lemoine A., Pegorier J.P., Parini A. Subcellular distribution of imidazoline-guanidinium-receptive sites in human and rabbit liver. Major localization to the mitochondrial outer membrane. JBiol Chem 1991, 26:155-160.
9. García-Sevilla J.A., Escribá P.V., Sastre M., Walzer C., Busquets X., Jaquet G., et al. Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Arch Gen Psychiatry 1996, 53:803-810.
10. Piletz J.E., Zhu H., Ordway G., Stockmeier C., Dilly G., Reis D., et al. Imidazoline receptor proteins are decreased in the hippocampus of individuals with major depression. Biol Psychiatry 2000, 48:910-919.
11. García-Sevilla J.A., Escribá P.V., Walzer C., Bouras C., Guimón J. Imidazoline receptor proteins in brains of patients with Alzheimer's disease. Neurosci Lett 1998, 247:95-98.
12. Reynolds G.P., Boulton R.M., Pearson S.J., Hudson A.L., Nutt D.J. Imidazoline binding sites in Huntington's and Parkinson's disease putamen. Eur J Pharmacol 1996, 301:R19-R21.
13. Nutt D.J., French N., Handley S., Hudson A., Husbands S., Jackson H., et al. Functional studies of specific imidazoline-2 receptor ligands. Ann NY Acad Sci 1995, 763:125-139.
14. 2 receptors. Eur J Pharmacol 1998, 353:123-135.
15. Hudson A.L., Tyacke R.J., Lalies M.D., Davies N., Finn D.P., Martí O., et al. Novel ligands for the investigation of imidazoline receptors and their binding proteins. Ann NY Acad Sci 2003, 1009:302-308.
16. 11C]benazoline. J Label Compd Radiopharm 2003, 46:1141-1149.
17. 2 binding site. NeuroImage 2010, 52:S127-S128.
18. 11C]FTIMD). Nucl Med Biol 2010, 37:625-635.
19. 2 selective ligands. Bioorg Med Chem 2001, 9:585-592.
20. 2 imidazoline receptors in the monkey brain. Synapse 2011, 65:452-455.
21. 11C]Ro15-1788 for PET studies of benzodiazepine receptors. Int J Appl Radiat Isot 1985, 36:971-976.
22. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., et al. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci 2007, 27:10957-10968.
23. 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:209-216.
24. 3H]2-(2-benzofuranyl)-2-imidazoline (BFI) to human brain: potentiation by tranylcypromine. Life Sci 1997, 60:605-615.
25. 2 binding site ligand, in rat brain. Eur J Pharmacol 2002, 450:55-60.
26. 3H]harmane, an endogenous beta-carboline, in rat brain. Neuropharmacology 2006, 50:269-276.